Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 268
Filter
1.
J Nutr Health Aging ; 24(3): 300-304, 2020.
Article in English | MEDLINE | ID: mdl-32115611

ABSTRACT

OBJECTIVES: Metabolic syndrome (MetS) represents a cluster of obesity and insulin resistance-related comorbidities. Abdominal obesity, hypertension, elevated triglyceride and glucose levels are components of MetS and may have a negative effect on cognitive function, but few cognitive studies have examined the combined risk severity. We sought to determine which specific cognitive abilities were associated with MetS in older adults at risk of cognitive decline. DESIGN: Cross-sectional study. PARTICIPANTS: 108 AIBL Active participants with memory complaints and at least one cardiovascular risk factor. MEASUREMENTS: Cardiovascular parameters and blood tests were obtained to assess metabolic syndrome criteria. The factors of MetS were standardized to obtain continuous z-scores. A battery of neuropsychological tests was used to evaluate cognitive function. RESULTS: Higher MetS z-scores were associated with poorer global cognition using ADAS-cog (adjusted standardized beta=0.26, SE 0.11, p<0.05) and higher Trail Making B scores (adjusted beta=0.23, SE 0.11, p<0.05). Higher MetS risk was related to lower cognitive performance. CONCLUSION: Combined risk due to multiple risk factors in MetS was related to lower global cognitive performance and executive function. A higher MetS risk burden may point to opportunities for cognitive testing in older adults as individuals may experience cognitive changes.


Subject(s)
Cardiovascular Diseases/etiology , Cognition/physiology , Cognitive Dysfunction/etiology , Metabolic Syndrome/complications , Aged , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Risk Factors
3.
Intern Med J ; 43(12): 1287-92, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23176405

ABSTRACT

BACKGROUND: Minimal trauma hip fractures are prevalent in Australia. The incidence rate and trend of hip fractures in Indigenous Western Australians have not been formally reported. AIMS: To evaluate incidence rates and trend of minimal trauma hip fractures in Indigenous and other Western Australians aged 40 years and over in 1999-2009 METHODS: Hip fracture data were obtained from an administrative database for all hospitalisations in Western Australia. Age-standardised incidence rates were calculated using direct standardisation, and standardised rate ratios were calculated using the indirect method. Trend in incidence rates were calculated using Poisson regression. RESULTS: In 1999-2009, 11,844 admissions for minimal trauma hip fractures were reported among Western Australians aged 40 years and over, of which 201 were recorded as indigenous. The age-standardised hip fracture rate was 273.0 (95% confidence interval (CI) 230.7-315.4) per 100,000 person-years for indigenous adults and 148.8 (95% CI 146.1-151.5) per 100,000 person-years for non-indigenous adults. The standardised morbidity ratio was 2.2 (95% CI 1.9-2.5). Over this period, age-standardised rates increased by an average of 7.2% per year among indigenous adults (P = 0.006), whereas non-indigenous rates fell by an average of 3.4% per year (P < 0.001). The relatively higher rates among indigenous adults were more evident in the younger age groups. CONCLUSION: There is a widening gap in minimal trauma hip fracture rates between indigenous and other Western Australians. This study demonstrates a need for public health review and management strategies to reduce falls and hip fracture in the indigenous community.


Subject(s)
Accidental Falls , Hip Fractures/diagnosis , Hip Fractures/ethnology , Native Hawaiian or Other Pacific Islander/ethnology , Population Surveillance , Adult , Aged , Aged, 80 and over , Female , Hip Fractures/epidemiology , Humans , Male , Middle Aged , Population Surveillance/methods , Western Australia/epidemiology , Western Australia/ethnology
4.
Intern Med J ; 42(4): 422-7, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21118407

ABSTRACT

BACKGROUND: Computed tomography (CT) of the brain in delirium investigation has a low yield of identifiable causes. We sought to identify the best clinical predictors of an intracranial cause of delirium. METHODS: We performed a case-control study of patients admitted to a delirium unit. Clinical factors of patients with positive findings on scans were compared with those without demonstrated causes. The main outcome measure was intracranial abnormalities accountable for the cause of delirium. RESULTS: During 18 months, there were 300 admissions to the unit. Mean age of patients was 86.6 years. Among 200 patients who proceeded to CT scanning, only 29 demonstrated intracranial pathology accountable for the cause of delirium, with a yield of 14.5%. There were 13 patients with ischaemic stroke, seven with subdural haemorrhage and nine with intracerebral haemorrhage. In multivariate analysis, new neurological deficits (adjusted odds ratio (OR) 18.17, 95% confidence interval (CI) 5.99-55.15), recent falls history (adjusted OR 5.58, 95% CI 1.90-16.42) and decline in conscious level (adjusted OR 4.58, 95% CI 1.33-15.79) were predictors of clinically meaningful radiological findings. Twenty-six of the 29 patients with scans had these three predictors with a sensitivity of 89.7% (95% CI 78.6-100%). CONCLUSION: We identified a history of recent fall as a new independent predictor for clinically relevant intracranial pathology in delirious patients, besides new neurological deficits and decline in conscious state. A flow chart incorporating CT head scanning as part of delirium investigation is proposed.


Subject(s)
Brain Diseases/complications , Brain/pathology , Delirium/diagnostic imaging , Delirium/etiology , Aged , Aged, 80 and over , Australia , Brain/diagnostic imaging , Case-Control Studies , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Risk Factors , Sensitivity and Specificity , Tomography, X-Ray Computed
5.
Phys Rev Lett ; 105(17): 173602, 2010 Oct 22.
Article in English | MEDLINE | ID: mdl-21231044

ABSTRACT

Nonlinear optical effects can be enhanced in tapered optical fibers with diameters less than the wavelength of the propagating light. Here we report on the observation of two-photon absorption using tapered fibers in rubidium vapor at power levels of less than 150 nW. Transit-time broadening produces two-photon absorption spectra with sharp peaks that are very different from conventional line shapes.

6.
Curr Top Microbiol Immunol ; 317: 1-38, 2008.
Article in English | MEDLINE | ID: mdl-17990788

ABSTRACT

Liver failure associated with hepatitis C virus (HCV) accounts for a substantial portion of liver transplantation. Although current therapy helps some patients with chronic HCV infection, adverse side effects and a high relapse rate are major problems. These problems are compounded in liver transplant recipients as reinfection occurs shortly after transplantation. One approach to control reinfection is the combined use of specific antivirals together with HCV-specific antibodies. Indeed, a number of human and mouse monoclonal antibodies to conformational and linear epitopes on HCV envelope proteins are potential candidates, since they have high virus neutralization potency and are directed to epitopes conserved across diverse HCV genotypes. However, a greater understanding of the factors contributing to virus escape and the role of lipoproteins in masking virion surface domains involved in virus entry will be required to help define those protective determinants most likely to give broad protection. An approach to immune escape is potentially caused by viral infection of immune cells leading to the induction hypermutation of the immunoglobulin gene in B cells. These effects may contribute to HCV persistence and B cell lymphoproliferative diseases.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Hepatitis C Antibodies/therapeutic use , Hepatitis C/therapy , Amino Acid Sequence , B-Lymphocytes/immunology , B-Lymphocytes/virology , Epitopes , Genes, env , Hepacivirus/genetics , Hepacivirus/immunology , Hepatitis C Antibodies/biosynthesis , Humans , Molecular Sequence Data , Neutralization Tests , Somatic Hypermutation, Immunoglobulin , Viral Envelope Proteins/immunology
7.
Minerva Gastroenterol Dietol ; 53(1): 1-7, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17415341

ABSTRACT

AIM: The pathogenesis of viral hepatitis involves the activation of cellular immunity, including intrahepatic lymphocytes (IHL). Lym-phocyte phenotypes play a fundamental role in the pathogenesis of chronic hepatitis C virus (HCV) infection, the progression of liver fibrosis and subsequent hepatocellular carcinoma. The aim of this study was to evaluate the frequency of intrahepatic mononuclear cell phenotypes in patients with chronic HCV. Another aim was to assess the relationship of nonparenchymal cells with liver fibrosis. METHODS: Liver fibrosis was evaluated with the Histologic Activity Index. Fourteen liver biopsies showed mild fibrosis (group 1), and 11 bridging fibrosis (group 2). Fourteen samples were explants from HCV patients who underwent liver transplantation (group 3). CD4 and CD8 T-lymphocytes, CD20 (B lymphocytes), CD16 (macrophage), and CD57 (NK) cells were detected using monoclonal antibodies on paraffin-embedded tissue. RESULTS: A minority of lobular cells stained for T- or B-lymphocytes. Most lobular cells stained with macrophage antibodies, and were more common in bridging fibrosis, compared to mild fibrosis. The percentages of lobular CD4 and CD8 cells were significantly lower in regenerative nodules of cirrhotic livers. There was a strong negative correlation between lobular CD8 and fibrosis score (R= -0.65), and a strong positive correlation between CD16-stained mononuclear cells (macrophages) and fibrosis score (R=0.66). In portal and periportal areas, CD4 but not CD8 lymphocytes decreased in parallel with fibrosis. B-lymphocytes were more commonly found in the portal areas than in the lobule. CD57-positive cells were rare in both lobule and portal areas, and their frequency was not different in the three groups studied. CONCLUSIONS: In hepatitis C, lobular mononuclear cells are mostly macrophages and appear associated with bridging fibrosis. Cirrhotic livers display significantly lower numbers of lobular CD4 and CD8 lymphocytes. This finding could help explain a decrease in immune surveillance and the promotion of neoplastic growth in HCV-associated cirrhosis.


Subject(s)
Hepatitis C, Chronic/genetics , Hepatitis C, Chronic/immunology , Lymphocytes , Hepatitis C, Chronic/complications , Humans , Liver Cirrhosis/complications , Phenotype
8.
Br J Ophthalmol ; 91(1): 111-5, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17179125

ABSTRACT

We report a case of bilateral mitochondrial optic neuropathies secondary to long-term linezolid treatment, show the nature of recovery, review the findings in the literature and propose a potential mitochondrial mechanism for linezolid-induced mitochondrial optic neuropathy. This is an observational case report and literature review with presentation of the clinical course of linezolid mitochondrial optic neuropathies through clinical and psychophysical documentation. Main outcome measures included: visual acuity, funduscopical examinations and peripapillary retinal nerve fibre layer (PRNFL) optical coherence tomography (OCT). A 6-year-old boy presented with bilateral optic neuropathies secondary to 1 year of linezolid treatment for osteomyelitis of the mandible. On presentation, visual acuities were 20/400 in both eyes, with considerable optic disc oedema, hyperaemia and PRNFL swelling confirmed by OCT. 2 weeks after the discontinuation of linezolid, visual acuities returned to 20/25 in both eyes, with reduction in the optic disc oedema, hyperaemia and PRNFL swelling. 3 months after the discontinuation of linezolid treatment, visual acuities were stable at 20/20 in both eyes, with a marked decrease in PRNFL swelling confirmed by OCT, and the development of mild temporal optic disc pallor in both eyes. Doctors should be aware of impairments of vision among patients on long-term linezolid treatment and promptly discontinue treatment to prevent irreversible vision loss. The development and resolution of bilateral optic neuropathies with considerable PRNFL swelling in this patient provide insight into the more general rubric of mitochondrial optic neuropathies.


Subject(s)
Acetamides/adverse effects , Anti-Infective Agents/adverse effects , Optic Nerve Diseases/chemically induced , Oxazolidinones/adverse effects , Child , Fluorescein Angiography/methods , Humans , Linezolid , Male , Mandibular Diseases/drug therapy , Mitochondrial Diseases/chemically induced , Nerve Fibers/drug effects , Osteomyelitis/drug therapy , Retina/drug effects , Vision Disorders/chemically induced , Visual Acuity/drug effects
9.
Curr Top Microbiol Immunol ; 307: 25-45, 2006.
Article in English | MEDLINE | ID: mdl-16903219

ABSTRACT

HDV replicates its circular RNA genome using a double rolling-circle mechanism and transcribes a hepatitis delta antigen-encodeing mRNA from the same RNA template during its life cycle. Both processes are carried out by RNA-dependent RNA synthesis despite the fact that HDV does not encode an RNA-dependent RNA polymerase (RdRP). Cellular RNA polymerase II has long been implicated in these processes. Recent findings, however, have shown that the syntheses of genomic and antigenomic RNA strands have different metabolic requirements, including sensitives to alpha-amanitin and the site of synthesis. Evidence is summarized here for the involvement of other cellular polymerases, probably pol I, in the synthesis of antigenomic RNA strand. The ability of mammalian cells to replicate HDV RNA implies that RNA-dependent RNA synthesis was preserved throughout evolution.


Subject(s)
Hepatitis Delta Virus/genetics , RNA, Viral/biosynthesis , Hepatitis Delta Virus/physiology , Hepatitis delta Antigens/chemistry , Hepatitis delta Antigens/physiology , RNA, Viral/chemistry , Transcription, Genetic , Virus Replication
10.
Int Braz J Urol ; 31(3): 204-11, 2005.
Article in English | MEDLINE | ID: mdl-15992422

ABSTRACT

PURPOSE: To evaluate the efficacy of adjuvant intravesical doxorubicin in superficial transitional cell carcinoma of the urinary bladder on long-term follow-up. MATERIALS AND METHODS: Between July 1986 and November 1991, all patients harboring superficial bladder cancers (Ta or T1) with one or more of these criteria (stage>a, grade>1, size>1 cm, multiple or recurrent tumors) were randomized to receive either 50 mg doxorubicin or no adjuvant therapy. Patients with recurrences were allowed to receive doxorubicin or other intravesical agents. Recurrence, progression and survival were analyzed. RESULTS: There were 82 patients included (64 males and 18 females). The mean age was 64 years. Forty-six patients were randomized to the doxorubicin group and 36 to the control group. Final analysis was made at median follow-up of 45, 128 and 131.5 months for recurrence, progression and survival, respectively. Recurrence free, progression free and disease specific survival did not differ significantly between groups. The 10-year Kaplan-Meier estimates for recurrence free, progression free and disease specific survival were 67%, 84% and 92%, respectively for the doxorubicin group, and were 50%, 89% and 97%, respectively for the control group. Tumor size predicted recurrence (p=0.013) and grade predicted progression (p=0.004) with multivariate analysis. CONCLUSIONS: Adjuvant intravesical doxorubicin could not be shown to improve recurrence, progression and survival of superficial bladder cancer, compared with control on long-term follow-up. Tumor size and grade were shown to be prognostic factors for recurrence and progression, respectively.


Subject(s)
Antibiotics, Antineoplastic/administration & dosage , Carcinoma, Transitional Cell/drug therapy , Doxorubicin/administration & dosage , Urinary Bladder Neoplasms/drug therapy , Administration, Intravesical , Adult , Aged , Aged, 80 and over , Antibiotics, Antineoplastic/therapeutic use , Carcinoma, Transitional Cell/mortality , Case-Control Studies , Chemotherapy, Adjuvant , Disease Progression , Disease-Free Survival , Doxorubicin/therapeutic use , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/prevention & control , Prognosis , Prospective Studies , Treatment Outcome , Urinary Bladder Neoplasms/mortality
11.
Int. braz. j. urol ; 31(3): 204-213, May-June 2005.
Article in English | LILACS | ID: lil-411094

ABSTRACT

PURPOSE: To evaluate the efficacy of adjuvant intravesical doxorubicin in superficial transitional cell carcinoma of the urinary bladder on long-term follow-up. MATERIALS AND METHODS: Between July 1986 and November 1991, all patients harboring superficial bladder cancers (Ta or T1) with one or more of these criteria (stage > a, grade > 1, size > 1 cm, multiple or recurrent tumors) were randomized to receive either 50 mg doxorubicin or no adjuvant therapy. Patients with recurrences were allowed to receive doxorubicin or other intravesical agents. Recurrence, progression and survival were analyzed. RESULTS: There were 82 patients included (64 males and 18 females). The mean age was 64 years. Forty-six patients were randomized to the doxorubicin group and 36 to the control group. Final analysis was made at median follow-up of 45, 128 and 131.5 months for recurrence, progression and survival, respectively. Recurrence free, progression free and disease specific survival did not differ significantly between groups. The 10-year Kaplan-Meier estimates for recurrence free, progression free and disease specific survival were 67 percent, 84 percent and 92 percent, respectively for the doxorubicin group, and were 50 percent, 89 percent and 97 percent, respectively for the control group. Tumor size predicted recurrence (p = 0.013) and grade predicted progression (p = 0.004) with multivariate analysis. CONCLUSIONS: Adjuvant intravesical doxorubicin could not be shown to improve recurrence, progression and survival of superficial bladder cancer, compared with control on long-term follow-up. Tumor size and grade were shown to be prognostic factors for recurrence and progression, respectively.


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Antibiotics, Antineoplastic/administration & dosage , Carcinoma, Transitional Cell/drug therapy , Doxorubicin/administration & dosage , Urinary Bladder Neoplasms/drug therapy , Administration, Intravesical , Antibiotics, Antineoplastic/therapeutic use , Case-Control Studies , Chemotherapy, Adjuvant , Carcinoma, Transitional Cell/mortality , Disease Progression , Disease-Free Survival , Doxorubicin/therapeutic use , Follow-Up Studies , Neoplasm Recurrence, Local/prevention & control , Prognosis , Prospective Studies , Treatment Outcome , Urinary Bladder Neoplasms/mortality
12.
Curr Top Microbiol Immunol ; 287: 95-131, 2005.
Article in English | MEDLINE | ID: mdl-15609510

ABSTRACT

As the largest RNA virus, coronavirus replication employs complex mechanisms and involves various viral and cellular proteins. The first open reading frame of the coronavirus genome encodes a large polyprotein, which is processed into a number of viral proteins required for viral replication directly or indirectly. These proteins include the RNA-dependent RNA polymerase (RdRp), RNA helicase, proteases, metal-binding proteins, and a number of other proteins of unknown function. Genetic studies suggest that most of these proteins are involved in viral RNA replication. In addition to viral proteins, several cellular proteins, such as heterogeneous nuclear ribonucleoprotein (hnRNP) A1, polypyrimidine-tract-binding (PTB) protein, poly(A)-binding protein (PABP), and mitochondrial aconitase (m-aconitase), have been identified to interact with the critical cis-acting elements of coronavirus replication. Like many other RNA viruses, coronavirus may subvert these cellular proteins from cellular RNA processing or translation machineries to play a role in viral replication.


Subject(s)
Coronavirus/physiology , Viral Proteins/physiology , Virus Replication/physiology , Aconitate Hydratase/metabolism , Coronavirus/enzymology , Heterogeneous-Nuclear Ribonucleoproteins/metabolism , Poly(A)-Binding Proteins/metabolism , Polypyrimidine Tract-Binding Protein/metabolism
13.
J Neurol Neurosurg Psychiatry ; 75(5): 776-8, 2004 May.
Article in English | MEDLINE | ID: mdl-15090580

ABSTRACT

A 50 year old man developed tonic-clonic seizures while receiving cyclosporin A after orthotopic cardiac transplant. The seizures resolved after cessation of cyclosporin A. Thirteen months later, he developed diplopia from bilateral internuclear ophthalmoplegia while receiving intravenous FK506. A temporal association was found between his symptoms and the serum FK506 concentrations. Withdrawal of the intravenous FK506 led to prompt resolution of the bilateral internuclear ophthalmoplegia.


Subject(s)
Heart Transplantation , Immunosuppressive Agents/adverse effects , Ocular Motility Disorders/chemically induced , Tacrolimus/adverse effects , Graft Rejection/drug therapy , Humans , Immunosuppressive Agents/administration & dosage , Male , Middle Aged , Ocular Motility Disorders/diagnosis , Tacrolimus/administration & dosage
14.
Cell Mol Life Sci ; 58(9): 1276-95, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11577984

ABSTRACT

Hepatitis C virus (HCV), a positive-sense, single-stranded RNA virus of the Flaviviridae family, is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide. Its RNA is difficult to study because biological materials are scarce and RNA replication is of low efficiency. This review focuses on the structure and functions of HCV RNA along with their biological and clinical significance. Despite the challenging characteristics of HCV, significant progress has been made in understanding the properties of HCV RNA and developing viral replication systems toward the improvement of antiviral therapies.


Subject(s)
Hepacivirus/genetics , RNA, Viral/genetics , Base Sequence , Carcinoma, Hepatocellular/virology , Flaviviridae/genetics , Hepacivirus/physiology , Hepatitis C/virology , Humans , Liver Cirrhosis/virology , Liver Neoplasms/virology , Molecular Sequence Data , Nucleic Acid Conformation , RNA, Viral/chemistry , RNA, Viral/classification , Virus Replication
15.
J Neurovirol ; 7(5): 432-6, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11582515

ABSTRACT

Coronaviruses, mouse hepatitis virus (MHV) strains, exhibit various degrees of neurotropism and hepatotropism following intracerebral (IC) infection of 4-week-old C57Bl/6 mice. Whereas MHV-A59 produces acute meningitis, encephalitis, hepatitis, and chronic demyelination, a closely related strain, MHV-2, produces only acute meningitis and hepatitis. We previously reported that the spike glycoprotein gene of MHV contains determinants of demyelination and hepatitis. To further investigate the site of demyelination and hepatitis determinants within the S gene, we sequenced the S gene of several nondemyelinating recombinant viruses. We found that three encephalitis-positive, demyelination-negative, hepatitis-negative recombinant viruses have an MHV-A59-derived S gene, which contains three identical point mutations (I375M, L652I, and T1087N). One or more of the sites of these mutations in the MHV-A59 genome are likely to contribute to demyelination and hepatitis.


Subject(s)
Cardiovirus Infections/virology , Demyelinating Diseases/virology , Encephalitis, Viral/virology , Genes, Viral , Hepatitis, Viral, Animal/virology , Membrane Glycoproteins/genetics , Meningitis, Viral/virology , Murine hepatitis virus/genetics , Point Mutation , Viral Envelope Proteins/genetics , Viral Structural Proteins/genetics , Amino Acid Substitution , Animals , Brain/pathology , Brain/virology , Cardiovirus Infections/pathology , Demyelinating Diseases/pathology , Encephalitis, Viral/pathology , Hepatitis, Viral, Animal/pathology , Liver/pathology , Liver/virology , Male , Membrane Glycoproteins/chemistry , Membrane Glycoproteins/physiology , Meningitis, Viral/pathology , Mice , Mice, Inbred C57BL , Murine hepatitis virus/classification , Murine hepatitis virus/pathogenicity , Murine hepatitis virus/physiology , Recombination, Genetic , Sequence Analysis, RNA , Species Specificity , Spike Glycoprotein, Coronavirus , Spinal Cord/pathology , Spinal Cord/virology , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/physiology , Virulence/genetics
16.
Antivir Chem Chemother ; 12 Suppl 1: 143-7, 2001.
Article in English | MEDLINE | ID: mdl-11594681

ABSTRACT

Hepatitis C virus (HCV) infection is emerging as one of the most prevalent viral diseases of medical significance. It afflicts approximately 100 million people worldwide. Although HCV infections are mostly clinically inapparent during the acute stage, the majority of infected patients develop chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Mainly as a result of ongoing HCV epidemics, the incidence of hepatocellular carcinoma and demands for liver transplantation have increased at a rapid pace in many countries in the last couple of decades. The current therapeutic options for HCV are limited; interferon-alpha (IFN-alpha) alone or IFN plus ribavirin are the only available treatments. Unfortunately, these treatments are efficacious for only a limited number of patients. They are particularly ineffective against genotype 1 HCV, which is the most common genotype in developed countries, including most European countries, the USA and Japan. Therefore, the development of new therapeutic strategies is urgently needed, so that the progression of hepatic diseases in HCV-infected patients can be halted before serious late-stage illnesses manifest themselves. Otherwise, HCV may exact a huge toll on health care budgets and the wellbeing of societies in the ensuing decades.


Subject(s)
Antiviral Agents/pharmacology , DNA-Directed RNA Polymerases/metabolism , Hepacivirus/drug effects , Hepacivirus/enzymology , Humans , Interferon-alpha/pharmacology , Ribavirin/pharmacology , Substrate Specificity
17.
J Virol ; 75(22): 10779-86, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11602719

ABSTRACT

The hepatitis B virus posttranscriptional regulatory element (PRE) is an RNA element that increases the expression of unspliced mRNAs, apparently by facilitating their export from the nucleus. We have identified a cellular protein that binds to the PRE as the polypyrimidine tract binding protein (PTB), which shuttles rapidly between the nucleus and the cytoplasm. Mutants of the PRE with mutations in PTB binding sites show markedly decreased activity, while cells that stably overexpress PTB show increased PRE-dependent gene expression. Export of PTB from the nucleus, like PRE function, is blocked by a mutant form of Ran binding protein 1 but not by leptomycin B. Therefore, PTB is important for PRE activity and appears to function as an export factor for PRE-containing mRNAs.


Subject(s)
Cell Nucleus/metabolism , Hepatitis B virus/genetics , RNA, Viral/metabolism , RNA-Binding Proteins/physiology , Ribonucleoproteins/physiology , Base Sequence , Binding Sites , Humans , Molecular Sequence Data , Polypyrimidine Tract-Binding Protein , RNA Precursors/metabolism , RNA, Messenger/metabolism , Transcription, Genetic , Tumor Cells, Cultured
18.
Yale J Biol Med ; 74(2): 89-94, 2001.
Article in English | MEDLINE | ID: mdl-11393265

ABSTRACT

BACKGROUND: Our study used data collected in Chung-Hsing Village in May 1998 to evaluate the prevalence of hypertension and its correlates in Taiwanese elderly people. METHODS: All of individuals aged 65 and over were recruited as study subjects. A total of 1,093 persons, out of 1,774 registered residents, were contacted by face-to-face interview The response rate was 61.6 percent. However, only 586 respondents had blood tests and completed questionnaires. Analysis in this study was based on these 586 subjects. In order to study the significant correlates of hypertension, the t-test, chi-square analysis, and multivariate logistic regression were used. RESULTS: Our results showed that 66 percent were men and 34 percent were women. The mean age was 73.1 +/- 5.3 years. The proportions of hypertension were 53.09 percent in men and 56.06 percent in women (p > 0.05). After controlling the other covariates, the multivariate logistic regression analysis showed that the significant related factors of hypertension were obesity (OR = 1.88, 95 percent CI = 1.06-3.34, p < 0.05) and renalfunction impairment (OR = 1.69, 95 percent CI = 1.02-2.80, p < 0.05). CONCLUSIONS: The prevalence of hypertension was high in elderly people. Hypertension is significantly associated with obesity and renalfunction impairment in elderly people.


Subject(s)
Hypertension/epidemiology , Age Distribution , Aged , Chi-Square Distribution , Female , Humans , Hypertension/diagnosis , Male , Multivariate Analysis , Obesity/complications , Obesity/epidemiology , Prevalence , Risk Factors , Sex Distribution , Socioeconomic Factors , Taiwan/epidemiology
19.
Virology ; 283(2): 178-87, 2001 May 10.
Article in English | MEDLINE | ID: mdl-11336543

ABSTRACT

Hepatitis C virus (HCV) core protein has been shown to interact with the death domain (DD) of tumor necrosis factor receptor-1 (TNFR1). In this study, we further examined the interaction of the core protein with the signaling molecules of TNFR1, including FADD, TRADD, and TRAF2, in a human embryonic kidney cell line, HEK-293, that overexpresses the HCV core protein. This core protein-expressing cell line exhibited enhanced sensitivity to TNF-induced apoptosis. By in vitro binding and in vivo coimmunoprecipitation assays, we showed that the HCV core protein interacted with the DD of FADD and enhanced apoptosis induced by FADD overexpression. This enhancement could be blocked by a dominant-negative mutant of FADD. In contrast, the core protein did not directly interact with the DD of TRADD, but could disrupt the binding of TRADD to TNFR1. TRAF2 recruitment to the TNFR1 signaling complex was also disrupted by the core protein. Correspondingly, TRAF2-dependent activation of the protein kinase JNK was suppressed in the core protein-expressing cells. However, NF kappa B activation by TNF was not significantly altered by the HCV core protein, suggesting the existence of TRAF2-independent pathways for NF kappa B activation. These results combined indicate that the HCV core protein sensitizes cells to TNF-induced apoptosis primarily by facilitating FADD recruitment to TNFR1. The inhibition of JNK activation by the HCV core protein may also contribute to the increased propensity of cells for apoptosis. These results, in comparison with other published studies, suggest that the effects of the HCV core protein and their underlying mechanisms vary significantly among cells of different origins.


Subject(s)
Adaptor Proteins, Signal Transducing , Apoptosis/physiology , Carrier Proteins/metabolism , Hepacivirus , JNK Mitogen-Activated Protein Kinases , Proteins/metabolism , Receptors, Tumor Necrosis Factor/metabolism , Tumor Necrosis Factor Receptor-Associated Peptides and Proteins , Viral Core Proteins/metabolism , Animals , Carrier Proteins/genetics , Cell Line , Fas-Associated Death Domain Protein , Gene Expression Regulation , Humans , MAP Kinase Kinase 4 , Mice , Mitogen-Activated Protein Kinase Kinases/metabolism , Proteins/genetics , Receptors, Tumor Necrosis Factor/genetics , Signal Transduction , TNF Receptor-Associated Death Domain Protein , TNF Receptor-Associated Factor 1 , TNF Receptor-Associated Factor 2 , Transfection , Viral Core Proteins/genetics
20.
J Virol ; 75(11): 5009-17, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11333880

ABSTRACT

The 3'-untranslated region (3'-UTR) of mouse hepatitis virus (MHV) RNA regulates the replication of and transcription from the viral RNA. Several host cell proteins have previously been shown to interact with this regulatory region. By immunoprecipitation of UV-cross-linked cellular proteins and in vitro binding of the recombinant protein, we have identified the major RNA-binding protein species as heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1). A strong hnRNP A1-binding site was located 90 to 170 nucleotides from the 3' end of MHV RNA, and a weak binding site was mapped at nucleotides 260 to 350 from the 3' end. These binding sites are complementary to the sites on the negative-strand RNA that bind another cellular protein, polypyrimidine tract-binding protein (PTB). Mutations that affect PTB binding to the negative strand of the 3'-UTR also inhibited hnRNP A1 binding on the positive strand, indicating a possible relationship between these two proteins. Defective-interfering RNAs containing a mutated hnRNP A1-binding site have reduced RNA transcription and replication activities. Furthermore, hnRNP A1 and PTB, both of which also bind to the complementary strands at the 5' end of MHV RNA, together mediate the formation of an RNP complex involving the 5'- and 3'-end fragments of MHV RNA in vitro. These studies suggest that hnRNP A1-PTB interactions provide a molecular mechanism for potential 5'-3' cross talks in MHV RNA, which may be important for RNA replication and transcription.


Subject(s)
3' Untranslated Regions/metabolism , 5' Untranslated Regions/metabolism , Heterogeneous-Nuclear Ribonucleoprotein Group A-B , Murine hepatitis virus/metabolism , RNA-Binding Proteins/metabolism , Ribonucleoproteins/metabolism , 3' Untranslated Regions/genetics , Animals , Base Sequence , Binding Sites , Blotting, Northern , Heterogeneous Nuclear Ribonucleoprotein A1 , Heterogeneous-Nuclear Ribonucleoproteins , Mutation , Nucleic Acid Conformation , Polypyrimidine Tract-Binding Protein , Precipitin Tests , Protein Binding , RNA, Viral/biosynthesis , RNA, Viral/genetics , Recombinant Proteins/metabolism , Ribonucleoproteins/biosynthesis , Transcription, Genetic , Viral Proteins/genetics , Viral Proteins/metabolism , Virus Replication
SELECTION OF CITATIONS
SEARCH DETAIL
...